Panbela Therapeutics, Inc.
(NASDAQ : PBLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.60%163.540.7%$1305.95m
LLYEli Lilly & Co. -1.93%323.651.1%$1056.02m
ABBVAbbVie, Inc. -5.84%134.381.9%$793.06m
PFEPfizer Inc. -0.75%43.830.9%$778.51m
BMYBristol-Myers Squibb Co. -0.82%71.121.0%$763.08m
MRKMerck & Co., Inc. -0.52%86.190.7%$687.90m
AZNAstraZeneca Plc -0.13%54.841.0%$411.81m
NVSNovartis AG -0.73%76.010.2%$216.26m
GSKGSK Plc 0.31%29.450.3%$214.53m
ALNYAlnylam Pharmaceuticals, Inc. -4.41%200.168.2%$210.64m
GBTGlobal Blood Therapeutics, Inc. 0.04%68.105.4%$190.73m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.21%151.220.0%$178.64m
IDXXIDEXX Laboratories, Inc. -1.81%325.803.9%$175.84m
HZNPHorizon Therapeutics Plc -1.28%61.895.4%$160.55m
NVONovo Nordisk A/S -0.74%99.650.1%$140.44m

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.